Diversity, Equity and Inclusion:
Management-level aspirational goals: Between the end of 2017 and the end of 2021, the percentage of women in management positions globally increased from 41% to 48%. Representation of minority group members (MGMs) in U.S. management positions also increased during this time, from 16% at the end of 2017 to 24% at the end of 2021.
Clinical Trial Diversity
Lilly has established clear, measurable goals to increase diversity in our trials to better understand how the medicines we develop work for the patients who will be taking them.
These goals include:
• Working to enroll trial participants who match the composition of the patient population that might use the trial’s medicine.
• Creating a robust clinical trial strategy and reaching diverse populations.
• Intentionally selecting a diverse range of trial sites and investigators.
• Increasing diverse representation through partnerships and collaboration.
Racial Justice Commitment
In 2020, Lilly and the Lilly Foundation launched the Racial Justice Commitment to help decrease the burden of racial injustice and its effects on communities of color. As part of this effort, Lilly pledged 25,000 volunteer hours and the Lilly Foundation committed $25 million over five years. The Racial Justice Commitment aims to drive change across five areas: internal people development, health equity, social impact, diversity partners and family sustaining jobs.
Since 2020, Lilly has nearly tripled its spending Black vendors and suppliers nationally and doubled our spending in Indianapolis. Additionally, Lilly has eliminated barriers to family-sustaining jobs at Lilly by removing the requirement for a four-year degree, for some jobs, through its Skills First Apprenticeship programs.
Racial Justice Commitment Grants
The Lilly Foundation awarded more than $10 million in grants in 2021 to combat racial injustice and inequity in Indianapolis. Funding to date has supported the launch of the Indianapolis Urban League Entrepreneurship Center to assist minority entrepreneurs with developing, sustaining and growing small businesses in Central Indiana and surrounding counties. Grants also supported the creation of the Business Equity for Indy Committee, a joint committee of the Indy Chamber of Commerce and the Central Indiana Corporate Partnership.
Diversity-Driven Talent Acquisition
Since 2018, we have offered diverse slates of candidates to ensure that leaders look beyond their own perspective and cast the widest net for the best talent. In addition, we strive to provide diverse interview teams for open positions. Our campus recruiting team helps establish the Lilly brand at each of our target universities. We build strong interpersonal relationships with university leaders, faculty, career services and student organizations – including veterans and disability offices on campus. We partner with national and local diversity conferences and a wide range of professional associations such as the National Society of Black Engineers (NSBE), the Society of Hispanic Professional Engineers (SHPE) and National Black MBA Association (NBMBAA) and top colleges and universities. This includes Hispanic Serving Institutions (HSIs) and Historically Black Colleges and Universities (HBCUs).
Climate Action Strategy
Reducing our energy and emissions by making our overall operations more efficient
Replacing carbon-intensive processes and energy sources with low-carbon alternatives
Offsetting remaining emissions and energy sources that could not be reduced or replaced by purchasing emissions offsets from high-quality carbon reduction projects (as it is not currently possible to eliminate all emissions sources or transition all direct energy supplies to renewable sources)
2030 Climate Goals
• 100% of purchased electricity from renewable sources
• Carbon neutral in our own operations (Scope 1 and 2 emissions)
• Enhance tracking and reporting of emissions from our full value-chain
• Zero waste to landfill
• 100% of plastic waste repurposed for beneficial use, with at least 90% recycled or reused
• Integrate sustainability into product and packaging design
• No adverse impact to water-stressed areas
• No adverse impact from pharmaceuticals in the environment
• Reduced absolute GHG emissions by 9% from 2020 to 2021.
• On-site solar arrays installed in France, Italy, Ireland, Spain and India. Active projects to add over 10 megawatts of solar capacity to our sites in Puerto Rico, Ireland and France.
• Invested over $50 million from our dedicated internal Energy and Waste Reduction Fund since 2006.
• 20 of our 26 sites achieved Zero waste to landfill in 2021, resulting in less than 1% of waste from routine operations.
• Recycled or reused approximately 284 billion liters of water in 2021, representing 98% of our water demand.
Encouraging Eco-Efficiency Across Our Operations
In 2006, we established the Energy, Waste and Water Reduction Fund to encourage projects that demonstrate the greatest potential for reductions in emissions and energy use but are not funded by site capital budgets. Since then, we have approved nearly $50 million supporting more than 190 projects. Since inception of the program, these projects collectively save more than one trillion BTUs of energy annually, avoiding over 129,000 metric tons of GHG emissions each year, measured as carbon dioxide equivalents.
Access & Affordability:
Globally, we’ve established a goal – Lilly 30x30 – to provide improved access to quality health care for 30 million people in resource-limited settings, annually, by 2030.
Lilly 30x30 is a company-wide effort and includes strategic collaborations with external partners, such as the Bill & Melinda Gates Foundation and Life for a Child, to improve access to quality healthcare for 30 million people in resource-limited settings, annually, by 2030. In early 2022, Lilly launched a new, $14.4M collaboration with UNICEF. Lilly also provides donations and support to nonprofit organizations, including the Lilly Foundation and the Lilly Cares Foundation.
We use a mix of philanthropy and shared value-based approaches to improve health systems and concentrate on diseases where we have deep technical expertise, including diabetes, cancer and, COVID-19.
For millions of people with diabetes, insulin is a life-saving medicine. Over the last century, this medical miracle has improved and extended countless lives around the world. Lilly takes its role as a leading diabetes company seriously – and that includes ensuring people have affordable access to treatments. Our programs are making an impact and helping at least 20,000 people each month better afford their insulin. Importantly, despite rising insurance deductibles, the average monthly out-of-pocket cost for Lilly insulin has dropped 44 percent, to $21.80, over the past five years.
Lilly Insulin Value Program
In April 2020, Lilly unveiled the Lilly Insulin Value Program, a new co-pay card that allows anyone with commercial insurance, or no insurance at all, to obtain their monthly prescription of Lilly insulin for $35 at retail pharmacies. In September 2020, we announced our long-term commitment to this program.